Articles with "pacmilimab" as a keyword



Photo by fachrizalm from unsplash

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sign Up to like & get
recommendations!
Published in 2021 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2021-002446

Abstract: Background Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from… read more here.

Keywords: probody; pacmilimab; solid tumors; pacmilimab ipilimumab ... See more keywords